Evotec AG stock analysis
Want to see EVO full AI Analyst Report?
Evotec AG (EVO) Stock Price & Analysis
EVO Stock Chart & Stats
- Day’s Range
- $1.57 - $1.63
- 52-Week Range
- $1.33 - $3.87
- Previous Close
- $1.66
- Volume
- N/A
- Average Volume (3M)
- 97.76K
- Market Cap
- $580.81M
- Enterprise Value
- $700.21M
- Total Cash (Recent Filing)
- $418.48M
- Total Debt (Recent Filing)
- $0
- Price to Earnings (P/E)
- ―
- Beta
- 1.10
- Next Earnings
- Apr 14, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Jan 11, 2019
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
D&PD Commercial Momentum
Strong D&PD sales growth, rising inbound leads, faster proposal turnaround, and customer-base expansion indicate improving commercial traction. These trends can support more reliable utilization of Evotec’s discovery platforms and strengthen its position with pharmaceutical and biotechnology partners over the next several quarters.
Vertex Commercial Manufacturing Partnership
Vertex’s selection provides a high-quality commercial manufacturing anchor for JEB and supports planned capacity expansion. A customer commitment at commercial scale can improve facility utilization, validate Evotec’s biologics platform, and create a foundation for additional manufacturing and partnership opportunities.
Horizon Cost Transformation
Savings delivered ahead of plan, alongside workforce and site-footprint actions, should create a more efficient cost base. If execution continues, Horizon can reduce operating drag, improve cash discipline, and help the business convert revenue growth and platform activity into stronger margins over the medium term.
Bears Say
Persistent Losses And Cash Burn
Evotec remains materially loss-making and consumes cash despite revenue growth and improved gross margin. Negative operating and free cash flow reduce internal funding capacity, increase reliance on liquidity or external financing, and constrain the company’s ability to invest while pursuing its transformation.
Declining Nine-month Revenue And EBITDA
The nine-month contraction shows that sales conversion, project timing, and delayed JEB activity are still weighing on realized performance. Continued volatility makes earnings less predictable and could delay the benefits of pipeline growth, partnerships, and cost reductions if revenue ramps remain uneven.
Liquidity Deterioration
A substantial quarterly liquidity decline is concerning while the company remains loss-making and cash-flow negative. Lower liquidity reduces financial flexibility, limits tolerance for further execution setbacks, and may force management to prioritize preservation of cash over capacity expansion or other strategic investments.
Evotec AG News
EVO FAQ
What was Evotec AG’s price range in the past 12 months?
What is Evotec AG’s market cap?
When is Evotec AG’s upcoming earnings report date?
How were Evotec AG’s earnings last quarter?
Is Evotec AG overvalued?
Does Evotec AG pay dividends?
What is Evotec AG’s EPS estimate?
How many shares outstanding does Evotec AG have?
What happened to Evotec AG’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Evotec AG?
What is the TipRanks Smart Score and how is it calculated?
Evotec AG Stock Smart Score
Company Description
Evotec AG
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Christian Wojczewski
- Employees
- 4,553
- Website
- www.evotec.com
- Address
- Essener Bogen 7, Hamburg, HA, 22419, DE
Evotec AG (EVO) Earnings & Revenues
EVO Company Deck
EVO Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive. Q3 performance improved materially, D&PD commercial indicators strengthened, Horizon savings were ahead of plan, the Vertex commercial-manufacturing selection advanced JEB, and full-year guidance was reaffirmed with expectations toward the upper end of the ranges. These positives outweighed the weaker nine-month revenue and EBITDA results, lower liquidity, delayed revenue conversion, lower expected Q4 milestones, and the planned 2027 manufacturing pause.
View all EVO earnings summariesEVO Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 6 | 14 |
| Technical Analysis | 2 | 6 | 2 |
| Moving Averages | 0 | 0 | 12 |












